Jump to content

Dextromethorphan: Difference between revisions

From Pharmacopedia
[pending revision][pending revision]
Assign pharmacological categories from List_of_CNS-active_medicines
Comprehensive categorization: +Morphinans, Dissociative Anesthetics, NMDA Receptor Antagonists
Line 34: Line 34:
[[Category:Psychedelics]]
[[Category:Psychedelics]]
[[Category:Dissociatives]]
[[Category:Dissociatives]]
[[Category:Morphinans]]
[[Category:Dissociative Anesthetics]]
[[Category:NMDA Receptor Antagonists]]

Revision as of 18:42, 15 May 2026

Dissociative
Dextromethorphan
DXM

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions6 edges
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP2D6 substrate major Primary 80 / 100
FDA Drug Interactions Table: sensitive index substrate of CYP2D6.
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Quinidine pk raises via CYP2D6 Inferred 76 / 100
Quinidine inhibits CYP2D6 (inhibitor_strong, intensity 95); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Fluoxetine pk raises via CYP2D6 Inferred 72 / 100
Fluoxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Paroxetine pk raises via CYP2D6 Inferred 72 / 100
Paroxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Bupropion pk raises via CYP2D6 Inferred 68 / 100
Bupropion inhibits CYP2D6 (inhibitor_strong, intensity 85); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Mirabegron pk raises via CYP2D6 Inferred 44 / 100
Mirabegron inhibits CYP2D6 (inhibitor_moderate, intensity 55); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
Inferred via Enzyme:CYP2D6 (exposure raised)

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Dissociative
Common uses
Pharmacy
Pharmacology
Purported mechanism
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor